Donation

Donate
Myeloma Minute
Topics
Dr. Suzanne Trudel ASH Abstract on Tocilizumab

Tocilizumab pre-treatment reduced cytokine release syndrome in relapsed/refractory multiple myeloma patients receiving cevostamab

February 3, 2023
ASH
Dr Shaji Kumar ASH abstract on the ASCENT trial

Fixed Duration Therapy with Dara-KRd for High Risk Smoldering Multiple Myeloma: ASCENT Trial

February 3, 2023
ASH
Dr. Sandy Wong ASH abstract on Alnuctumab

Alnuctamab, a BCMA x CD3 T-Cell Engager, in Patients with Relapsed/Refractory Multiple Myeloma

February 2, 2023
ASH
Dr Joseph Mikhael top ASH abstracts on health disparities

Multiple Myeloma Abstracts Dealing with Health Disparities Presented at ASH 2022

February 1, 2023
ASH
Dr Jesus Berdeja ASH abstract on BMS-986393

Clinical Activity of BMS-986393, a CAR T cell therapy directed at GPRC5D, in Pts with RRMM

February 1, 2023
ASH
Dr. Nizar Bahlis ASH abstract on MagnetisMM-3

Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma: MagnetisMM-3

January 30, 2023
ASH
Dr. Ashley Rosko on factors that influence transplant and survival

Multiple Myeloma Transplant: Examining the Intersection of Access, Age and Race

January 27, 2023
ASH
Is there a new highly sensitive blood test to detect minimal residual disease?

Is there a new highly sensitive blood test to detect minimal residual disease? 

January 26, 2023
Ask Dr. Durie
Dr. Tondre Buck abstract on race and myeloma risk assessment

Real-World Multiple Myeloma Risk Factors and Outcomes By Race/Ethnicity in the United States

January 16, 2023
ASH
Bispecifics Part 4: The Science of Bispecific Antibodies

Bispecifics Part 4: The Science of Bispecific Antibodies

January 13, 2023
Emerging Therapies
Dr. Ajai Chari abstract on MonumenTAL-1

Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1/2 Results from MonumenTAL-1

January 12, 2023
ASH
Dr. Saad Usmani abstract on KarMMa2

KarMMa2: Efficacy and Safety of Idecabtagene Vicleucel in High Risk Multiple Myeloma Pts with Early Relapse after ASCT

January 12, 2023
ASH

Give Where Most Needed

Learn More